17 Aug, 2021, 09:00 ET
VANCOUVER, BC, Aug. 17, 2021 /CNW/ - Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its abstract entitled In Vitro Activity and Efficacy of Novel Dual PARP-HDAC Inhibitors has been accepted for presentation at the upcoming joint meeting of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC), the 2021 Molecular Targets and Cancer Therapeutics conference will take place as a virtual event October 7-10, 2021. The conference has historically attracted academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.
"We look forward to presenting our work in developing precision medicines that selectively target and kill tumor cells at this prestigious meeting," said Prof. Mads Daugaard, Rakovina Therapeutics' president and chief scientific officer. "The meeting will represent the first opportunity to highlight promising new data being developed around our novel kt-3000 series of dual PARP-HDAC inhibitors as potential new therapies against treatment-resistant cancers."
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.
The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at www.sedar.com.
SOURCE Rakovina Therapeutics Inc.
For further information: Rakovina Therapeutics Inc., David Hyman, Chief Financial Officer, Email: [email protected]; Investor Relations Contact, [email protected]; Media Contact, [email protected]
Share this article